Momentum among stocks in the healthcare sector is tipped to continue in 2020 as a range of small and mid-sized biotech and medical device companies hope for clinical trial results before the year's end.
The healthcare vertical has been the best performer – up 34 per cent – of the ASX 200 indices this calendar year, and the bulk of the gains have come in the second half.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
